DrugPatentWatch Database Preview
Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Biologic Drug Details
Summary for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Tradenames: | 1 |
| Patents: | 5 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
US Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | ➤ Sign Up | Chevron Phillips Chemical Company LP (The Woodlands, TX) | ➤ Sign Up | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | ➤ Sign Up | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | ➤ Sign Up | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | ➤ Sign Up | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | ➤ Sign Up | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | ➤ Sign Up | ALDERBIO HOLDINGS LLC (Las Vegas, NV) | ➤ Sign Up | search | ||
| Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant | INJECTION, SUSPENSION | 125126 | 001 | 2006-06-08 | ➤ Sign Up | Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) | ➤ Sign Up | search | ||
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Patent Expiration | Status | Orphan | Source |
International Patents for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 5815098 | ➤ Sign Up |
| European Patent Office | 2367570 | ➤ Sign Up |
| Japan | 2009537176 | ➤ Sign Up |
| South Korea | 20170036814 | ➤ Sign Up |
| Taiwan | 201023888 | ➤ Sign Up |
| Japan | 2010528589 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 30/2001 | Austria | ➤ Sign Up | PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1) |
| 2016000049 | Germany | ➤ Sign Up | PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621 |
| C/GB10/043 | United Kingdom | ➤ Sign Up | PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526 |
| 2018 00020 | Denmark | ➤ Sign Up | PRODUCT NAME: AFUCOSYLERET ANTISTOF, DER BINDER TIL ALFA-UNDERENHEDEN AF DEN HUMANE INTERLEUKIN-5-RECEPTOR, SAERLIGT BENRALIZUMAB ELLER EN TERAPEUTISK AEKVIVALENT VARIANT DERAF, SOM ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/17/1252 20180110 |
| C/GB94/014 | United Kingdom | ➤ Sign Up | PRODUCT NAME: RECOMBINANT HUMAN FACTOR- VIII (BHK); REGISTERED: NL 16789 19940419; NL 16790 19940419; NL 16791 19940419; UK 0010/0194 19940517; UK 0010/0195 19940517; UK 0010/0196 19940517 |
| C/GB06/025 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
